New discovery! Melatonin may be expected to help treat new coronary pneumonia

For the study, researchers developed a new artificial intelligence platform to help identify potential drugs that could treat COVID-19.
researchers have found that melatonin may be a candidate for COVID-19.
analyzed data from COVID-19 patients enrolled at the Cleveland Clinic, the researchers said that when adjusting for age, race, smoking history, and complications from multiple diseases, participants were about 30 percent less likely to test positive for SARS-CoV-2.
noted that for African-Americans, the probability of testing positive for the virus increased from 30 percent to 52 percent if the same variables were adjusted.
researcher Dr Feixiong Cheng said the findings did not mean people could take melatonin on their own without consulting a clinician.
large-scale observational studies and randomized controlled trials in late 2000s were critical to confirming the clinical efficacy of melatonin in PATIENT-19 patients, and we found a correlation in this study, which will be further studied later. In the
article, the researchers used online medical methods and large-scale electronic health records from clinic patients to identify common clinical manifestations and pathological mechanisms between COVID-19 and other diseases, in particular, the closer the researchers measured the proximity between the cesod gene white and the 64 other diseases associated with it in a variety of disease classifications, the closer the two were to the pathological association between diseases, including malignant cancer, autoimmune diseases, and cardiovascular disease.
researchers say the proteins associated with respiratory distress syndrome and sepsis, two leading causes of death in severe COVID-19 patients, or are highly relevant to a variety of SARS-CoV-2 proteins, may tell researchers that using drugs already approved to treat these respiratory diseases may be able to target biological targets that could have some effect on the treatment of COVID-19.
In the end, the researchers found that autoimmune, lung and neurological diseases had significant network approximations to the genetic whiteness of SARS-CoV-2, and identified 34 drugs or candidates for redirection, including melatonin.
Finale researcher Cheng said recent studies have shown that COVID-19 is a systemic disease that affects multiple cell types, tissues and organs, so understanding the complex interactions between viruses and other diseases may be key to uncovering COVID-19-related complications and identifying new redirected drugs.
this paper provides a powerful, comprehensive network medicine strategy that may help researchers predict the manifestations of COVID-19-related diseases and advance scientists' search for new and effective therapies.
original source: Yadi Zhou et al. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19, PLoS Biology (2020). DOI:10.1371/journal.pbio.3000970